Equities research analysts expect Mediwound Ltd (NASDAQ:MDWD) to announce sales of $800,000.00 for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Mediwound’s earnings. The lowest sales estimate is $380,000.00 and the highest is $1.10 million. Mediwound reported sales of $530,000.00 in the same quarter last year, which would suggest a positive year over year growth rate of 50.9%. The company is expected to announce its next quarterly earnings report before the market opens on Monday, March 25th.

On average, analysts expect that Mediwound will report full-year sales of $3.26 million for the current fiscal year, with estimates ranging from $2.79 million to $3.50 million. For the next fiscal year, analysts expect that the business will report sales of $12.41 million, with estimates ranging from $5.81 million to $18.30 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that cover Mediwound.

MDWD has been the subject of several analyst reports. Zacks Investment Research lowered Mediwound from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 16th. Oppenheimer set a $15.00 target price on Mediwound and gave the company a “buy” rating in a report on Tuesday, January 22nd.

A number of institutional investors have recently bought and sold shares of the business. Migdal Insurance & Financial Holdings Ltd. grew its position in Mediwound by 1.3% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,126,058 shares of the biopharmaceutical company’s stock worth $13,075,000 after purchasing an additional 27,781 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Mediwound by 37.4% in the third quarter. Renaissance Technologies LLC now owns 179,300 shares of the biopharmaceutical company’s stock valued at $1,103,000 after acquiring an additional 48,800 shares in the last quarter. Jefferies Group LLC acquired a new position in shares of Mediwound in the third quarter valued at about $1,272,000. Nexthera Capital LP grew its stake in shares of Mediwound by 288.3% in the third quarter. Nexthera Capital LP now owns 173,076 shares of the biopharmaceutical company’s stock valued at $1,064,000 after acquiring an additional 128,500 shares in the last quarter. Finally, Worth Venture Partners LLC acquired a new position in shares of Mediwound in the third quarter valued at about $306,000. Institutional investors own 30.00% of the company’s stock.

Shares of Mediwound stock traded up $0.02 during mid-day trading on Wednesday, reaching $5.24. 988 shares of the stock traded hands, compared to its average volume of 117,277. Mediwound has a fifty-two week low of $3.76 and a fifty-two week high of $7.35. The stock has a market capitalization of $141.20 million, a P/E ratio of -8.29 and a beta of 0.69.

About Mediwound

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Featured Article: What is Considered a Good Return on Equity (ROE)?

Get a free copy of the Zacks research report on Mediwound (MDWD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mediwound (NASDAQ:MDWD)

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.